Contrasting Concentra Group Holdings Parent (NYSE:CON) & Revvity (NYSE:RVTY)

Revvity (NYSE:RVTY) and Concentra Group Holdings Parent (NYSE:CON) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Insider and Institutional Ownership

86.7% of Revvity shares are owned by institutional investors. 0.7% of Revvity shares are owned by insiders. Comparatively, 6.6% of Concentra Group Holdings Parent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Revvity and Concentra Group Holdings Parent’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revvity	8.44%	7.52%	4.61%
Concentra Group Holdings Parent	7.33%	48.42%	5.90%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Revvity and Concentra Group Holdings Parent, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	1	5	8	0	2.50
Concentra Group Holdings Parent	1	1	4	0	2.50

Revvity currently has a consensus price target of $114.75, suggesting a potential upside of 9.90%. Concentra Group Holdings Parent has a consensus price target of $27.75, suggesting a potential upside of 34.97%. Given Concentra Group Holdings Parent’s higher probable upside, analysts clearly believe Concentra Group Holdings Parent is more favorable than Revvity.

Earnings & Valuation

This table compares Revvity and Concentra Group Holdings Parent”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.81 billion	4.21	$270.39 million	$1.99	52.47
Concentra Group Holdings Parent	$1.90 billion	1.39	$166.54 million	$1.20	17.13

Revvity has higher revenue and earnings than Concentra Group Holdings Parent. Concentra Group Holdings Parent is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Revvity has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Concentra Group Holdings Parent has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500.

Dividends

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.3%. Concentra Group Holdings Parent pays an annual dividend of $0.25 per share and has a dividend yield of 1.2%. Revvity pays out 14.1% of its earnings in the form of a dividend. Concentra Group Holdings Parent pays out 20.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Summary

Revvity beats Concentra Group Holdings Parent on 10 of the 15 factors compared between the two stocks.

About Revvity

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

About Concentra Group Holdings Parent

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers’ compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.